Despite their favourable survival outcomes, the median progression‐free survival (PFS) of patients with advanced NSCLC treated with PD‐1/PD‐L1 inhibitors plus chemotherapy is only 5–8 months.5, 6, 7. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.